Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 02/28/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Phathom Pharmaceuticals, Inc. - PHATPRNewsWire • 02/23/23
ROSEN, LEADING INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHATPRNewsWire • 02/22/23
ROSEN, Top Ranked Investor Counsel, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHATNewsfile Corp • 02/17/23
ROSEN, Leading Investor Counsel, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHATNewsfile Corp • 02/08/23
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHATPRNewsWire • 01/31/23
PHAT SHAREHOLDER ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHATPRNewsWire • 01/24/23
PHAT EQUITY ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHATNewsfile Corp • 01/16/23
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Phathom Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 01/12/23
PHAT INVESTOR ALERT: ROSEN, A LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHATPRNewsWire • 01/12/23
PHAT Equity Alert: ROSEN, A Leading Law Firm, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHATNewsfile Corp • 01/11/23
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)GlobeNewsWire • 01/08/23
Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive EsophagitisGlobeNewsWire • 01/03/23
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - PHATPRNewsWire • 12/02/22
PHAT NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHATPRNewsWire • 11/23/22
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business UpdatesGlobeNewsWire • 11/08/22
Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare ConferencesGlobeNewsWire • 11/03/22
PHAT LOSS ALERT: ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHATPRNewsWire • 11/01/22
Phathom Pharmaceuticals Announces Placement of the Remaining $40 Million in Non-Dilutive Capital under its up to $300 Million Revenue Interest Financing AgreementGlobeNewsWire • 11/01/22
Phathom Pharmaceuticals Completes Patient Enrollment in Phase 3 PHALCON-NERD-301 Daily Dosing Trial of Vonoprazan in Non-Erosive Gastroesophageal Reflux Disease (NERD)GlobeNewsWire • 10/24/22